SCHEMBL4418029

SCHEMBL4418029

CCOC(C=O)CCOCCC(C=O)OCC

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.32
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13597508 0.81
SCHEMBL4641210 0.77
SCHEMBL9848753 0.77 ALDH1A1 (0.36) THRBLMNA
SCHEMBL11098658 0.76 THRB (0.31) THRB
SCHEMBL3880423 0.75
SCHEMBL8906574 0.74 THRB (0.33) THRBLMNA
SCHEMBL31347979 0.74 ADH1B (0.42) LMNA
SCHEMBL10567526 0.74
SCHEMBL8829654 0.74 TSHR (0.30)
SCHEMBL11219107 0.74 ADH1B (0.42) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090326239-A1 FERMENTATIVE PREPARATION PROCESS FOR AND CRYSTAL FORMS OF CYTOSTATICS HOFMANN HANS 2009-12-31 US disclosed
US-20070197611-A1 Fermentative preparation process for and crystal forms of cytostatics HOFMANN HANS 2007-08-23 US disclosed
US-7101702-B2 Fermentative preparation process for and crystal forms of cytostatics NOVARTIS AG (CH) 2006-09-05 US disclosed
US-6656711-B2 Concentrating epothilones in culture from Sorangium strains obtained by mutagenesis; antitumor agents NOVARTIS AG (CH) 2003-12-02 US disclosed
US-20030220379-A1 Fermentative preparation process for and crystal forms of cytostatics HOFMANN HANS (CH) 2003-11-27 US disclosed
US-20020165256-A1 Fermentative preparation process for and crystal forms of cytostatics HOFMANN HANS (CH) 2002-11-07 US disclosed
US-6194181-B1 PRODUCING EPOTHIOLONES IN A CULTURE MEDIUM BY PROVIDING MICROORGANISMS SUCH AS MYXOBACTERIA WHICH PRODUCE EPOTHIOLONES, AND ADDING A COMPLEX-FORMING AGENT SOLUBLE IN THE CULTURE MEDIUM, SUCH AS CYCLODEXTRINS; ANTITUMOR AGENTS NOVARTIS AG (CH) 2001-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220379-A1 Fermentative preparation process for and crystal forms of cytostatics TALDO1, PYCR1, THPO THRB 3007/4885LMNA 3638/4885
US-20020165256-A1 Fermentative preparation process for and crystal forms of cytostatics TALDO1, PYCR1, THPO THRB 3007/4885LMNA 3638/4885
US-20070197611-A1 Fermentative preparation process for and crystal forms of cytostatics TALDO1, PYCR1, THPO THRB 3057/4885LMNA 3593/4885
US-20090326239-A1 FERMENTATIVE PREPARATION PROCESS FOR AND CRYSTAL FORMS OF CYTOSTATICS TALDO1, PYCR1, THPO THRB 3007/4885LMNA 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.